Barclays Maintains Equal-Weight on West Pharmaceutical Servs, Raises Price Target to $275

Benzinga Newsdesk www.benzinga.com Positive 71.9%

Neg 0% Neu 0% Pos 71.9%

Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Equal-Weight and raises the price target from $265 to $275.